Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium, Abbott end research deal

As expected, ABT and MLNM ended a five-year, 2001 deal to discover, develop and market compounds for Type II

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE